Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02325739 · ClinicalTrials.gov registry record · Phase 1
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
NCT02325739 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 172 participants.
The verdict
NCT02325739, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
Study Summary
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid malignancies based on RECIST 1.1.
Interventions
- BIOLOGICAL PDR001
- DRUG FGF401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2014-12-29 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02325739
The ClinicalTrials.gov registry entry for NCT02325739 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT02325739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02325739 about?
NCT02325739 is a clinical study titled "FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression". Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid malignancies based on RECIST 1.1.
What is the current status of trial NCT02325739?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2014-12-29. Estimated completion is 2019-05-30.
What interventions are being tested in trial NCT02325739?
The interventions under investigation include: PDR001 (BIOLOGICAL), FGF401 (DRUG).
Who is sponsoring clinical trial NCT02325739?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.